Description
This combination formulation pairs a DAC-free CJC-1295 GHRH analog with the selective GHS-R1a agonist Ipamorelin, enabling the study of dual-receptor GH release amplification through concurrent hypothalamic pathway engagement. For research use only.
- Synergistic GH Pulse Amplification: Investigated for supra-additive GH release via simultaneous GHRH-R activation (CJC-1295) and ghrelin receptor agonism (Ipamorelin), producing enhanced pulse amplitude beyond either agent alone.
- Clean Somatotroph Selectivity: Studied for combined GH-axis stimulation with minimal perturbation of ACTH-cortisol, prolactin, and aldosterone axes owing to Ipamorelin’s receptor selectivity profile.
- IGF-1 Dose-Response Optimization: Explored for characterizing the relationship between dual-agonist GH pulse parameters and downstream hepatic IGF-1 production via the JAK2-STAT5b signaling cascade.









Reviews
There are no reviews yet.